Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transvamix for chronic pain in epidermolysis bullosa
NL-OMON51174Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Transvamix in epidermolysis bullosa (EB) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Reduction in pain unpleasantness. Planned start May 2021; status: not yet recruiting.
02
Drugs
Transvamix
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NL-OMON51174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51174.